The Prevalence of Multimorbidity Among Genitourinary Cancer Patients in Chile: A Retrospective Population-Based Study
Abstract
:1. Introduction
2. Material and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Gauld, R.; Blank, R.; Burgers, J.; Cohen, A.B.; Dobrow, M.; Ikegami, N.; Kwon, S.; Luxford, K.; Millett, C.; Wendt, C. The World Health Report 2008-Primary Healthcare: How Wide Is the Gap between Its Agenda and Implementation in 12 High-Income Health Systems? Healthc. Policy 2012, 7, 38–58. [Google Scholar] [CrossRef] [PubMed]
- Skou, S.T.; Mair, F.S.; Fortin, M.; Guthrie, B.; Nunes, B.P.; Miranda, J.J.; Boyd, C.M.; Pati, S.; Mtenga, S.; Smith, S.M. Multimorbidity. Nat. Rev. Dis. Primers 2022, 8, 48. [Google Scholar] [CrossRef] [PubMed]
- Vogeli, C.; Shields, A.E.; Lee, T.A.; Gibson, T.B.; Marder, W.D.; Weiss, K.B.; Blumenthal, D. Multiple Chronic Conditions: Prevalence, Health Consequences, and Implications for Quality, Care Management, and Costs. J. Gen. Intern. Med. 2007, 22, 391–395. [Google Scholar] [CrossRef] [PubMed]
- Ritchie, C.S.; Kvale, E.; Fisch, M.J. Multimorbidity: An Issue of Growing Importance for Oncologists. J. Oncol. Pract. 2011, 7, 371–374. [Google Scholar] [CrossRef] [PubMed]
- Sarfati, D.; Koczwara, B.; Jackson, C. The Impact of Comorbidity on Cancer and Its Treatment. CA Cancer J. Clin. 2016, 66, 337–350. [Google Scholar] [CrossRef] [PubMed]
- Raghavan, D.; Skinner, E. Genitourinary Cancer in the Elderly. Semin. Oncol. 2004, 31, 249–263. [Google Scholar] [CrossRef] [PubMed]
- Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D.M.; Piñeros, M.; Znaor, A.; Bray, F. Cancer Statistics for the Year 2020: An Overview. Int. J. Cancer 2021, 149, 778–789. [Google Scholar] [CrossRef] [PubMed]
- Parra-Soto, S.; Petermann-Rocha, F.; Martínez-Sanguinetti, M.A.; Leiva-Ordeñez, A.M.; Troncoso-Pantoja, C.; Ulloa, N.; Diaz-Martínez, X.; Celis-Morales, C.; Parra-Soto, S.; Petermann-Rocha, F.; et al. Cáncer En Chile y En El Mundo: Una Mirada Actual y Su Futuro Escenario Epidemiológico. Rev. Med. Chil. 2020, 148, 1489–1495. [Google Scholar] [CrossRef] [PubMed]
- Yeung, C.; Dinh, T.; Lee, J. The Health Economics of Bladder Cancer: An Updated Review of the Published Literature. Pharmacoeconomics 2014, 32, 1093–1104. [Google Scholar] [CrossRef] [PubMed]
- FONASA. FONASA NOTA METODOLÓGICA Indicadores Panel FONASA; FONASA: Santiago, Chile, 2023. [Google Scholar]
- FONASA. FONASA Base de Datos GRD FONASA; FONASA: Santiago, Chile, 2023. [Google Scholar]
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Koppie, T.M.; Serio, A.M.; Vickers, A.J.; Vora, K.; Dalbagni, G.; Donat, S.M.; Herr, H.W.; Bochner, B.H. Age-Adjusted Charlson Comorbidity Score Is Associated with Treatment Decisions and Clinical Outcomes for Patients Undergoing Radical Cystectomy for Bladder Cancer. Cancer 2008, 112, 2384–2392. [Google Scholar] [CrossRef] [PubMed]
- Lee, L.; Cheung, W.Y.; Atkinson, E.; Krzyzanowska, M.K. Impact of Comorbidity on Chemotherapy Use and Outcomes in Solid Tumors: A Systematic Review. J. Clin. Oncol. 2011, 29, 106–117. [Google Scholar] [CrossRef] [PubMed]
- Xiao, H.; Tan, F.; Goovaerts, P.; Adunlin, G.; Ali, A.A.; Gwede, C.K.; Huang, Y. Impact of Comorbidities on Prostate Cancer Stage at Diagnosis in Florida. Am. J. Mens. Health 2016, 10, 285–295. [Google Scholar] [CrossRef] [PubMed]
- Post, P.N.; Kil, P.J.M.; Hendrikx, A.J.M.; Janssen-Heijnen, M.L.G.; Crommelin, M.A.; Coebergh, J.W.W. Comorbidity in Patients with Prostate Cancer and Its Relevance to Treatment Choice. BJU Int. 1999, 84, 652–656. [Google Scholar] [CrossRef]
- Ahmad, T.A.; Gopal, D.P.; Chelala, C.; Zm, A.; Ullah, D.; Taylor, S.J. Review Article Multimorbidity in People Living with and beyond Cancer: A Scoping Review. Am. J. Cancer Res. 2023, 13, 4346–4365. [Google Scholar] [PubMed]
- Kurnot, J.A.; Kaye, D.R. Reducing Financial Toxicity in Bladder Cancer Care. Curr. Opin. Urol. 2024, 34, 484–488. [Google Scholar] [CrossRef] [PubMed]
% of Total N (Mean) | Testicular | Prostate | Bladder | Kidney | ||
---|---|---|---|---|---|---|
Age | <=47 | 29.7% (29) | 83% (30) | 7.1% (31) | 11.9% (31) | 32.2% (27) |
48–64 | 42.6% (58) | 15.6% (54) | 43.6% (60) | 55% (58) | 49.3% (57) | |
65–81 | 22.2% (72) | 1.3% (71) | 37.6% (72) | 27.5% (72) | 15.9% (72) | |
> or =82 | 5.5% (87) | 0.3% (93) | 11.7% (87) | 5.6% (86) | 2.6% (86) | |
Sex | Male | 83.1% | 73% | 60.8% | ||
Female | 16.9% | 27% | 39.2% |
Type of GUC | USD | |
---|---|---|
Bladder cancer | 14,426,893 | |
Prostate cancer | 28,443,679 | |
Kidney cancer | 18,109,217 | |
Testicular cancer | 6,572,191 | |
Total | 67,513,129 | p Value |
Without multimorbidity | a 20,164,165 | a p < 0.001 |
With multimorbidity | a 46,663,959 |
Genitourinary Cancer | |||||
---|---|---|---|---|---|
Bladder Cancer (N = 3489) | Prostate Cancer (N = 8191) | Kidney Cancer (N = 5659) | Testicular Cancer (N = 1453) | p Value | |
Hypertension | 51.8% | 57.7% | 57.4% | 10.4% | |
Type 2 diabetes mellitus | 22% | 24% | 26.9% | 3.5% | |
Urinary tract infection | 9.2% a | 8.7% | 3.2% | 1.6% | <0.001 |
Chronic kidney disease | 13.4% | 15.1% | 20.8% a | 2.2% | <0.001 |
Benign prostatic hyperplasia | 4.5% | 1.7% | 4.8% | 0.4% | |
Smoking | 8% a | 4.4% | 5.3% | 6.4% | <0.001 |
Anemia | 8.8% | 10.2% | 9.9% | 3.5% | |
Hematuria | 7.9% a | 4.5% | 1.9% | 0.4% | <0.001 |
With comorbidity | 70.8% | 73.6% | 71.9% | 21.9% | <0.001 |
Type of Admission | |||
---|---|---|---|
Elective | Emergency | p Value | |
Hypertension | 47% | 58.2% a | <0.01 |
Type 2 diabetes mellitus | 18.8% | 27.4% a | <0.01 |
Urinary tract infection | 10.1% | 22.1% a | <0.01 |
Chronic kidney disease | 3.2% | 11.6% a | <0.01 |
Anemia | 2.1% | 7.1% a | <0.01 |
Hematuria | 5.9% | 14.1% a | <0.01 |
Severity According to Comorbidity | |||
---|---|---|---|
No Multimorbidity | Multimorbidity | p Value | |
No severity | 20.2% | 5% | <0.001 |
Minor severity | 47.2% | 38.9% | <0.001 |
Moderate severity | 22.2% | 31.7% | <0.001 |
Major severity | 10.3% | 24.4% | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Published by MDPI on behalf of the Société Internationale d’Urologie. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Eltit, I.; Juri, D.; Delgado, I.; Cáceres, C.; Rojas, I.; Fernández, M.I. The Prevalence of Multimorbidity Among Genitourinary Cancer Patients in Chile: A Retrospective Population-Based Study. Soc. Int. Urol. J. 2025, 6, 14. https://doi.org/10.3390/siuj6010014
Eltit I, Juri D, Delgado I, Cáceres C, Rojas I, Fernández MI. The Prevalence of Multimorbidity Among Genitourinary Cancer Patients in Chile: A Retrospective Population-Based Study. Société Internationale d’Urologie Journal. 2025; 6(1):14. https://doi.org/10.3390/siuj6010014
Chicago/Turabian StyleEltit, Ignacio, Diego Juri, Iris Delgado, Camila Cáceres, Ignacio Rojas, and Mario I. Fernández. 2025. "The Prevalence of Multimorbidity Among Genitourinary Cancer Patients in Chile: A Retrospective Population-Based Study" Société Internationale d’Urologie Journal 6, no. 1: 14. https://doi.org/10.3390/siuj6010014
APA StyleEltit, I., Juri, D., Delgado, I., Cáceres, C., Rojas, I., & Fernández, M. I. (2025). The Prevalence of Multimorbidity Among Genitourinary Cancer Patients in Chile: A Retrospective Population-Based Study. Société Internationale d’Urologie Journal, 6(1), 14. https://doi.org/10.3390/siuj6010014